W
WAVEMAN · COMPANY
FORR · Forrester Research, Inc.
> Ask across nine datasets ⌘K
LIVE
TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475
← ALL COMPANIES

FORR

FORRESTER RESEARCH, INC.
PHARMA & BIOTECH · SERVICES-ENGINEERING, ACCOUNTING, RESEARCH, MANAGEMENT · CIK 0001023313
FORM 144 · 1☆ WATCH
INSIDER NET · 180D
-$198.9K
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
0
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
0
13F, latest reported quarter
REVENUE GROWTH
-8.2%
XBRL, annual
NET MARGIN
-30.1%
CONVERSIONS · 180D
16
codes C/M, not in net · $0 priced
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
net -$198.9K over 180 days
-$198.9K over 90 days
more than 52% of Pharma & Biotech
CONGRESS
no member of Congress has reported trading it
FUNDS
fewer than five institutions report holding it
REVENUE
-8.2% year over year
below 69% of Pharma & Biotech
MARGIN
-30.1% net margin
below 53% of Pharma & Biotech
BUYBACKS
$956.0K repurchased, FY to 2026-06-30
below 89% of Pharma & Biotech
SHORT
3.1% of shares outstanding short · 4.7 days to cover · settled 2026-07-31
below 56% of Pharma & Biotech
THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET
Insiders are net sellers: -$198.9K across 3 people in 180 days.
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN +30.1%
+30.1%12M
-47%-22%+4%+30%2025-092025-102025-122026-032026-052026-072026-09 2026-08-20 · Finn Leo Christian sold $82.4K2026-08-20 · Darrah Ryan sold $58.9K2026-08-13 · Johnson Carrie sold $57.5K2026-08-20 · Leo Christian Finn filed to sell $82.4K
INSIDER SELLFORM 144
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
Insiders have filed to sell — before selling.
The record shows a net $198.9K sold by insiders over 180 days, $82.4K in planned Form 144 sales. Every figure is a federal filing, dated the day it became public.
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, FORRESTER RESEARCH, INC. insiders sold a net $198.9K of stock across 47 Form 4 purchases and sales, with 0 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-05.

INSIDER
FILED
SHARES
VALUE
Finn Leo Christian
Chief Financial Officer
SELL
2026-08-20
7,000.0
$82.4K
Darrah Ryan
Chief Legal Officer
SELL
2026-08-20
5,000.0
$58.9K
Johnson Carrie
Chief Product Officer
SELL
2026-08-13
5,000.0
$57.5K
Facemire Michael
Chief Technology Officer
SELL
2024-08-05
719.0
$13.5K
Darrah Ryan
Chief Legal Officer
SELL
2024-08-05
3,895.0
$71.1K
47 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 42 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported

no 13F holders found for this ticker

SCHEDULE 13D/G
No 5%+ ownership filings
Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.
Planned sales · Form 144
Filed before the sale — intent, not a trade
Leo Christian Finn
FILED 2026-08-20
$82.4K
Executive pay vs shareholder return
DEF 14A pay-versus-performance disclosure · both the headline pay and the SEC's mark-to-market figure, beside the return the company delivered and the return of the peer group it chose itself
FY
CEO TOTAL
ACTUALLY PAID
OTHER NEOs AVG
TSR
PEER TSR
2025
$673.3K
$673.3K
$1.1M
-81%
+41%
2024
$215.3K
$215.3K
$970.8K
-63%
+18%
2023
$244.9K
$244.9K
$1.7M
-36%
+19%
2022
$992.6K
$992.6K
$978.3K
-15%
-2%
2021
$1.6M
$1.6M
$1.1M
+40%
+27%
TAGGED BY THE COMPANY UNDER SEC ITEM 402(v) · RETURN IS CUMULATIVE FROM THE START OF THE DISCLOSURE PERIOD · GREEN WHERE THE COMPANY BEAT ITS OWN PEER GROUP
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-122024-122023-122022-12
REVENUE$396.9M$432.5M$480.8M$537.8M
OPERATING INCOME$-113.2M$740.0K$6.8M$32.7M
NET INCOME$-119.4M$-5.7M$3.0M$21.8M
EPS (DILUTED)-6.28-0.300.161.14
OPERATING CASH FLOW$21.1M$-3.9M$21.7M$39.4M
CASH$63.3M$56.1M$72.9M$103.6M
LONG-TERM DEBT$0$35.0M$35.0M$50.0M
BUYBACKS$2.5M$15.9M$4.1M$15.1M
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-05 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-05 ALL SYSTEMS LIVE FOR MACHINES →